Who are Standard-dose intravenous tenecteplase's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Krazati, Lumakras, Dexilant, Nexium, Protonix, Pantoprazole Sodium.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/standard-dose-intravenous-tenecteplase.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Standard-dose intravenous tenecteplase — Competitive Intelligence Brief

Standard-dose intravenous tenecteplase (Standard-dose intravenous tenecteplase) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: tissue plasminogen activator. Area: Cardiovascular.

phase 3 tissue plasminogen activator tPA Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Standard-dose intravenous tenecteplase (Standard-dose intravenous tenecteplase) — The George Institute. Tenecteplase is a tissue plasminogen activator that works by catalyzing the conversion of plasminogen to plasmin, resulting in the breakdown of blood clots.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Standard-dose intravenous tenecteplase TARGET	Standard-dose intravenous tenecteplase	The George Institute	phase 3	tissue plasminogen activator	tPA
Krazati	ADAGRASIB	Bristol-Myers Squibb	marketed		GTPase KRas	2022-01-01
Lumakras	SOTORASIB	Amgen	marketed		GTPase KRas	2021-01-01
Dexilant	DEXLANSOPRAZOLE	Takeda	marketed	Proton Pump Inhibitor [EPC]	(H+, K+)-ATPase	2009-01-01
Nexium	esomeprazole	AstraZeneca	marketed	Proton pump inhibitor (PPI)	Potassium-transporting ATPase	2001-02-20
Protonix	Pantoprazole Sodium	Baxter	marketed	Proton pump inhibitor (PPI)	(H+, K+)-ATPase enzyme system	2000-01-01
Pantoprazole Sodium	Pantoprazole Sodium	Pfizer	marketed	Proton pump inhibitor (PPI)	(H+, K+)-ATPase enzyme	2000-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-06-07 — Pantoprazole Sodium · 7544370 · US
2026-12-07 — Pantoprazole Sodium · 7544370*PED · US

Sponsor landscape (tissue plasminogen activator class)

The George Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Standard-dose intravenous tenecteplase — Competitive Intelligence Brief. https://druglandscape.com/ci/standard-dose-intravenous-tenecteplase. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab